

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/600,718	06/20/2003	Leonel Merwe van Zyl	297/167	5862
25297 75	90 10/06/2006	EXAMINER		
•	LSON, TAYLOR & HU	TUNG, JOYCE		
3100 TOWER E SUITE 1200	BLVD	ART UNIT	PAPER NUMBER	
DURHAM, NC 27707			1637	
			DATE MAILED: 10/06/2006	5

Please find below and/or attached an Office communication concerning this application or proceeding.

			ation No.	Applicant(s)		
		10/600	),718	VAN ZYL, LEON	VAN ZYL, LEONEL MERWE	
Office Action Summary		Exami	ner	Art Unit		
		Joyce <sup>-</sup>	Tung	1637		
- Period fo	<ul> <li>The MAILING DATE of this community</li> <li>Reply</li> </ul>	ication appears on	the cover sheet	with the correspondence a	ddress	
WHIC - Extense after S - If NO - Failure Any re	PRTENED STATUTORY PERIOD FOR HEVER IS LONGER, FROM THE M. sions of time may be available under the provisions (SIX (6) MONTHS from the mailing date of this common period for reply is specified above, the maximum state to reply within the set or extended period for reply sply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	AILING DATE OF of 37 CFR 1.136(a). In no unication. tutory period will apply an will, by statute, cause the	THIS COMMUN be event, however, may d will expire SIX (6) MG application to become	IICATION.  a reply be timely filed  ONTHS from the mailing date of this ABANDONED (35 U.S.C. § 133).	,	
Status						
1)⊠	Responsive to communication(s) file	d on <i>05 Septembe</i>	er 2006			
		2b)⊠ This action is				
3)	Since this application is in condition	·—		atters, prosecution as to th	e merits is	
	closed in accordance with the practic			•		
Dispositio	on of Claims					
4)🖂	Claim(s) <u>1-20</u> is/are pending in the a	pplication.				
-	la) Of the above claim(s) is/ar	• •	consideration.			
	Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>17-20</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)[	Claim(s) are subject to restric	tion and/or election	n requirement.			
Application	on Papers					
9)[] 1	The specification is objected to by the	e Examiner.				
-	he drawing(s) filed on is/are:		b) objected to	by the Examiner.		
	Applicant may not request that any object				•	
[	Replacement drawing sheet(s) including	the correction is req	uired if the drawin	g(s) is objected to. See 37 C	FR 1.121(d).	
11)[] T	he oath or declaration is objected to	by the Examiner.	Note the attache	ed Office Action or form P	TO-152.	
Priority u	nder 35 U.S.C. § 119					
12) 🗌 A	Acknowledgment is made of a claim f	for foreign priority	under 35 U.S.C.	§ 119(a)-(d) or (f).		
	All b) Some * c) None of:	or torong represent		3 . / ( ( ) ( ) ( ) ( ) .		
	1. Certified copies of the priority	documents have b	een received.			
:	2. Certified copies of the priority			Application No		
	3. Copies of the certified copies of				l Stage	
	application from the Internation	•			•	
* S	ee the attached detailed Office action	n for a list of the ce	ertified copies no	ot received.		
Attachment(	'c)					
	of References Cited (PTO-892)		4) Interview	Summary (PTO-413)		
2) 🔲 Notice	of Draftsperson's Patent Drawing Review (P	TO-948)	Paper No	o(s)/Mail Date		
	ation Disclosure Statement(s) (PTO/SB/08)			Informal Patent Application		
Paper	No(s)/Mail Date		- 6)	·	•	

Application/Control Number: 10/600,718

Art Unit: 1637

#### **DETAILED ACTION**

The applicant's response filed 9/5/06 to the Office action has been entered. Claims 1-20 are pending.

### Election/Restrictions

- 1. Applicant's election without traverse of Group II, claims 17-20 in the reply filed on 9/05/06 is acknowledged. Since the response does not have a specific argument for the restriction requirement the election is considered without traverse.
- 2. Claims 1-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.

  Election was made without traverse in the reply filed on 9/5/06.

# Claim Rejections - 35 USC § 112

- 3. The following is a quotation of the second paragraph of 35 U.S.C. 112:
  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 4. Claim 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
  - a. Claim 18 is vague and indefinite because it is unclear what is meant by the phrase "the labeling mix is a 5X mixture". Does it mean that the mixture is 5 times diluted or 5 times concentrated? Clarification is required.

Application/Control Number: 10/600,718

Art Unit: 1637

ò

# Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. Claims 17-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shinoki et al. (US 2002/0064782, issued May 30, 2002).

Shinoki et al. disclose a fluorescent nucleotide, which is useful for efficient labeling of nucleic acids (See pg. 1, [0010]). The invention provides a process of preparing fluorescence-labeled nucleic acids, which comprises the step of conducting a reaction of the synthesis of nucleic acid by using nucleic acid synthetase, a nucleic acid as a template, and the fluorescent nucleotide of the present invention (See pg. 6[0059]). The nucleic acid synthetase is Klenow enzyme (See pg. 6, [0060]). The random prime method is one of the methods for labeling DNA in which hexanucleotide primer is used (See pg. 6, [0062]). The labeling mixture comprises dATP, dCTP, dGTP and dTTP and at least one of a fluorescently labeled nucleotide selected from the group consisting of dUTP-Cy3<sup>TM</sup> and dUTP-Cy5<sup>TM</sup> (See pg. 11, [0106]). The fluorescent nucleotide of the invention can be supplied in the form of a kit for detecting nucleic acid (See pg. 7 [0072]).

Shinoki et al. do no disclose the kit, which is for fluorescently labeling a nucleic acid including the components recited in the instant claims. However, Shinoki et al. disclose that types of reagents to be contained in the kit can be appropriately selected according to the purpose of the kit such reagent may include the fluorescent nucleotide, nucleic acid synthetase, buffer as

Application/Control Number: 10/600,718

Art Unit: 1637

well as a mixture of one or more (preferably four) non-fluorescent nucleotides, purified water or the like. The kit can further contain primers (See pg. 7, [0072]).

One of ordinary skill in the art would have been motivated to make the kit for fluorescently labeling a nucleic acid including the components recited in the instant claims as suggested by Shinoki et al. Moreover, it was also routine practice in the art to make a kit including all the components as needed for conveniently performing a method. It would have been <u>prima facie</u> obvious to make the kit for fluorescently labeling a nucleic acid

Shinoki et al. also do not disclose the ratio of dATP to dCTP to dGTP to dTTP to dUTP-Cy3 or dUTP-Cy5 is 8:8:8:1:1 as recited in claims 17 and 18.

Shinoki et al. disclose the concentration of dATP (500uM), dCTP (500uM), dGTP (500uM) to dTTP (200uM), dUTP-Cy3 (100uM) or dUTP-Cy5 (100uM) (See pg. 11, [0106])

One of ordinary skill in the art would have been motivated to optimize the ratio of dATP to dCTP to dTTP to dUTP-Cy3 or dUTP-Cy5 to be higher or lower than the ratio used in the method of Shinoki et al. because the optimization of the experiment condition, for example, the concentration of the reagent was routine practice in the art at the time of the instant invention filed. It would have been <u>prima facie</u> obvious to make the kit for fluorescently labeling a nucleic acid with the ratio of dATP to dCTP to dTTP to dUTP-Cy3 or dUTP-Cy5 as recited in claims 17 and 18.

### **Summary**

7. No claims are allowable.

Page 5

Application/Control Number: 10/600,718

Art Unit: 1637

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (571) 272-0790. The examiner can normally be reached on Monday - Friday, 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Joyce Tung September 28, 2006

KENNETH R. HORLICK, PH.D.

10/2/06